Sun Pharma To Acquire US based Checkpoint Therapeutics

India’s Sun Pharmaceutical Industries will acquire U.S.-based Checkpoint Therapeutics, a cancer treatment company, for $355 million.

This move aligns with Sun Pharma’s strategy to expand in oncology and immunotherapy. Last year, it partnered with Philogen for an anti-cancer drug.

The deal, expected to close in Q2 2025, will add UNLOXCYT, an FDA-approved skin cancer treatment, to Sun Pharma’s portfolio.

Sun Pharma will pay $4.10 per share in cash, a 66% premium over Checkpoint’s last closing price.

Read also- India Agreed To Cut Down Tariffs Because Somebody Finally Exposed Them: Trump's Latest "Massive Tariff" Claim

Dilip Shanghvi, Chairman & Managing Director of Sun Pharma, said, "Combining UNLOXCYT, an FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma, with Sun Pharma's global presence means patients with cSCC may soon have access to an important, new treatment option. The acquisition further bolsters our innovative portfolio in onco-derm therapy."

"I am proud of the dedication and passion of our team at Checkpoint that allowed us to achieve the first and only FDA-approved anti-PD-L1 treatment for patients with advanced cSCC, and we are excited to enter this transaction with Sun Pharma as the next step to bringing UNLOXCYT to cSCC patients in need of a differentiated immunotherapy treatment option," said James Oliviero, President and Chief Executive Officer of Checkpoint. "Sun Pharma is aligned with Checkpoint's commitment to improving the lives of skin cancer patients, and I believe this transaction will maximize value for our stockholders and provide accelerated access to UNLOXCYT in the United States, Europe and other markets worldwide."

Checkpoint is a Nasdaq-listed company that develops new treatments for solid tumor cancers.

The U.S. FDA has approved its drug UNLOXCYT to treat adults with advanced skin cancer (cSCC) who cannot undergo curative surgery or radiation.

About Sun Pharmaceutical Industries Limited

Sun Pharma is the world’s largest specialty generics company, operating in specialty medicines, generics, and consumer healthcare.

It is India’s biggest pharmaceutical company and a major player in the U.S. and emerging markets.

Sun Pharma’s fast-growing specialty portfolio includes treatments for skin, eye, and cancer-related skin conditions, making up over 18% of its sales.

With vertically integrated operations, it provides high-quality medicines trusted in 100+ countries. Its manufacturing facilities span six continents.

Startup Funding News: Your Gateway to Every Funding Update.

Latest Startup News: Stay updated with the latest startup news and trends. Your go-to source for startup ecosystem updates.

Startup Stories: Discover inspiring tales of startups overcoming challenges and achieving success.